JP2014509510A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014509510A5 JP2014509510A5 JP2013556805A JP2013556805A JP2014509510A5 JP 2014509510 A5 JP2014509510 A5 JP 2014509510A5 JP 2013556805 A JP2013556805 A JP 2013556805A JP 2013556805 A JP2013556805 A JP 2013556805A JP 2014509510 A5 JP2014509510 A5 JP 2014509510A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- seq
- chain variable
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 85
- 239000000427 antigen Substances 0.000 claims description 81
- 102000036639 antigens Human genes 0.000 claims description 81
- 108091007433 antigens Proteins 0.000 claims description 81
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 47
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 46
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims description 41
- 102000004889 Interleukin-6 Human genes 0.000 claims description 18
- 108090001005 Interleukin-6 Proteins 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 206010006895 Cachexia Diseases 0.000 claims description 7
- 208000027866 inflammatory disease Diseases 0.000 claims description 7
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims description 6
- 230000008827 biological function Effects 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 208000005024 Castleman disease Diseases 0.000 claims description 4
- 230000026731 phosphorylation Effects 0.000 claims description 4
- 238000006366 phosphorylation reaction Methods 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 102100031051 Cysteine and glycine-rich protein 1 Human genes 0.000 claims description 2
- 102000008946 Fibrinogen Human genes 0.000 claims description 2
- 108010049003 Fibrinogen Proteins 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 102000004495 STAT3 Transcription Factor Human genes 0.000 claims description 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 2
- 102000054727 Serum Amyloid A Human genes 0.000 claims description 2
- 108700028909 Serum Amyloid A Proteins 0.000 claims description 2
- 108091006374 cAMP receptor proteins Proteins 0.000 claims description 2
- 230000024245 cell differentiation Effects 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims description 2
- 229940012952 fibrinogen Drugs 0.000 claims description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000001594 aberrant effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 14
- 206010025482 malaise Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161449005P | 2011-03-03 | 2011-03-03 | |
| US61/449,005 | 2011-03-03 | ||
| PCT/US2012/026954 WO2012118813A2 (en) | 2011-03-03 | 2012-02-28 | Anti-il-6 receptor antibodies and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014509510A JP2014509510A (ja) | 2014-04-21 |
| JP2014509510A5 true JP2014509510A5 (enExample) | 2015-03-12 |
| JP6097702B2 JP6097702B2 (ja) | 2017-03-15 |
Family
ID=46753443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013556805A Expired - Fee Related JP6097702B2 (ja) | 2011-03-03 | 2012-02-28 | 抗ｉｌ−６受容体抗体およびその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8753634B2 (enExample) |
| EP (1) | EP2681243B1 (enExample) |
| JP (1) | JP6097702B2 (enExample) |
| KR (1) | KR20140043724A (enExample) |
| CN (1) | CN103502274B (enExample) |
| AU (1) | AU2012223449A1 (enExample) |
| BR (1) | BR112013021863A2 (enExample) |
| CA (1) | CA2827581A1 (enExample) |
| IL (2) | IL228275A (enExample) |
| MX (1) | MX342810B (enExample) |
| RU (1) | RU2013144392A (enExample) |
| WO (1) | WO2012118813A2 (enExample) |
| ZA (1) | ZA201306451B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102002104A (zh) | 2009-08-28 | 2011-04-06 | 江苏先声药物研究有限公司 | 一种抗vegf的单克隆抗体及含有该抗体的药物组合物 |
| US8753634B2 (en) | 2011-03-03 | 2014-06-17 | Apexigen, Inc. | Anti-IL-6 receptor antibodies and methods of use |
| WO2014052462A2 (en) * | 2012-09-25 | 2014-04-03 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
| JP6707445B2 (ja) | 2013-10-21 | 2020-06-10 | ジェネンテック， インコーポレイテッド | 抗Ｌｙ６Ｅ抗体及び使用方法 |
| JP2016208934A (ja) * | 2015-05-12 | 2016-12-15 | 学校法人日本大学 | 抗イヌインターロイキン−６受容体モノクローナル抗体又は抗体フラグメント及びその利用 |
| KR102709681B1 (ko) | 2015-07-31 | 2024-09-26 | 메디뮨 리미티드 | 헵시딘 매개 장애의 치료 방법 |
| WO2017201731A1 (en) | 2016-05-27 | 2017-11-30 | Beijing Vdjbio Co., Ltd. | Antibodies, composition and kits comprising same, and methods of use thereof |
| US20190330318A1 (en) | 2016-07-25 | 2019-10-31 | Biogen Ma Inc. | Anti-hspa5 (grp78) antibodies and uses thereof |
| RU2656160C2 (ru) | 2016-08-17 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека |
| MY191926A (en) | 2016-12-01 | 2022-07-18 | Regeneron Pharma | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
| CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| KR20190095931A (ko) | 2016-12-14 | 2019-08-16 | 프로제너티, 인크. | 섭취가능한 디바이스를 사용하여 방출된 il-12/il-23 저해제로의 위장관 질환의 치료 |
| WO2018112237A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor |
| SG10201912128SA (en) | 2017-02-01 | 2020-02-27 | Univ Yale | Treatment of diuretic resistance |
| US20210138213A1 (en) | 2017-03-30 | 2021-05-13 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| TW201904993A (zh) | 2017-06-22 | 2019-02-01 | 瑞士商諾華公司 | IL-1β 結合抗體之用途 |
| CN110959013A (zh) * | 2017-06-22 | 2020-04-03 | 埃派斯进有限公司 | 抗vista抗体和使用方法 |
| WO2018235056A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
| JP2021500856A (ja) * | 2017-09-13 | 2021-01-14 | 江蘇恒瑞医薬股▲ふん▼有限公司 | Ｉｌ−６ｒ抗体およびその抗原結合フラグメントならびに医薬としての使用 |
| WO2019136312A1 (en) | 2018-01-05 | 2019-07-11 | Corvidia Therapeutics, Inc. | Methods for treating il-6 mediated inflammation without immunosuppression |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| EP3810268A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| CN112805299B (zh) | 2018-10-05 | 2025-09-16 | 西雅图儿童医院以西雅图儿童研究机构名义经营 | 针对原发性免疫缺陷、胱氨酸病和威尔逊病的新生儿筛查 |
| US20220025036A1 (en) | 2018-12-21 | 2022-01-27 | Novartis Ag | Use of il-1beta binding antibodies |
| JP7501876B2 (ja) * | 2019-04-17 | 2024-06-18 | 国立大学法人広島大学 | Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤 |
| CN110124029B (zh) * | 2019-04-19 | 2023-08-11 | 中山大学附属第六医院 | Il-6r抗体及羊水干细胞在制备用于治疗nec的药物中的应用 |
| US20230287107A1 (en) * | 2019-07-23 | 2023-09-14 | Shanghaitech University | Asic1 channel antagonist antibody |
| JP2023519969A (ja) | 2020-03-31 | 2023-05-15 | シアトル・チルドレンズ・ホスピタル・ドゥーイング／ビジネス／アズ・シアトル・チルドレンズ・リサーチ・インスティテュート | リソソーム蓄積症に関するプロテオミクススクリーニング |
| CN115298215A (zh) * | 2020-04-02 | 2022-11-04 | 西雅图儿童医院以西雅图儿童研究机构名义经营 | 特异性地结合与原发性免疫缺陷：维斯科特-奥尔德里奇综合征和x连锁无丙种球蛋白血症相关的肽的抗体 |
| CN114729014A (zh) * | 2020-04-08 | 2022-07-08 | 纳诺皮技术有限公司 | 单克隆抗体及其用途 |
| US12454580B2 (en) | 2020-04-10 | 2025-10-28 | Regeneron Pharmaceuticals, Inc. | FRB antibodies |
| WO2021207697A1 (en) | 2020-04-10 | 2021-10-14 | Cantex Pharmaceuticals, Inc. | Treatment of acute lung injury |
| WO2021233246A1 (en) * | 2020-05-18 | 2021-11-25 | Biosion Inc. | Antibodies binding il6r and uses thereof |
| US20240316008A1 (en) | 2020-06-22 | 2024-09-26 | Tranquis Therapeutics, Inc. | Treatment of systemic immune activation syndromes |
| AR122933A1 (es) | 2020-07-10 | 2022-10-19 | Novo Nordisk As | Métodos para tratar la enfermedad cardiovascular |
| WO2022040604A1 (en) | 2020-08-21 | 2022-02-24 | BioAge Labs, Inc. | Use of dp1 receptor antagonists for the treatment of viral respiratory tract infections and dysregulated immune response in aged and aging patients |
| AU2021338354A1 (en) | 2020-09-02 | 2023-04-20 | Serhat GUMRUKCU | Expanded memory subsets of gamma delta T cells for immunotherapy |
| WO2022130409A1 (en) * | 2020-12-18 | 2022-06-23 | Dr. Reddy's Laboratories Limited | Il-6r targeting compositions with reduced heterogeneity in functional attributes |
| AU2023394987A1 (en) | 2022-12-15 | 2025-06-26 | Aarhus Universitet | Synthetic activation of multimeric transmembrane receptors |
| CN118085075B (zh) * | 2023-11-29 | 2024-08-30 | 武汉爱博泰克生物科技有限公司 | 抗人甲胎蛋白的兔单克隆抗体及其应用 |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
| US4237224A (en) | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
| JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| DE69329974T2 (de) | 1992-12-04 | 2001-07-19 | Medical Research Council, London | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| ATE204325T1 (de) | 1993-04-29 | 2001-09-15 | Unilever Nv | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5675063A (en) | 1995-02-28 | 1997-10-07 | Loyola University Of Chicago | Immortalized rabbit hybridoma fusion partner |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7657380B2 (en) | 2003-12-04 | 2010-02-02 | Xencor, Inc. | Methods of generating variant antibodies with increased host string content |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| CA2496523A1 (en) | 2002-08-30 | 2004-03-11 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Human antihuman interleukin-6 antibody and fragment of the antibody |
| JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス，インコーポレーテッド | 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法 |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US20060165696A1 (en) * | 2003-02-24 | 2006-07-27 | Chugai Seiyaku Kabushiki Kaisha Keio University | Remedy for spinal injury containing interleukin-6 antagonist |
| EP1673396A1 (en) | 2003-09-22 | 2006-06-28 | BioVation GmbH & Co.KG. | Use of antibodies for reducing the biological effectiveness of il-6 |
| DK1690550T3 (da) | 2003-10-17 | 2012-11-05 | Chugai Pharmaceutical Co Ltd | Terapeutisk middel til mesothelioma |
| AU2005274905B2 (en) | 2004-08-04 | 2010-12-23 | Mentrik Biotech, Llc | Variant Fc regions |
| EP1810980A1 (en) | 2004-10-28 | 2007-07-25 | Osaka University | Interleukin-6 inhibitors |
| US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| AU2005325801A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
| CA2602663A1 (en) | 2005-03-31 | 2006-10-05 | Xencor, Inc. | Fc variants with optimized properties |
| US7429487B2 (en) | 2005-07-05 | 2008-09-30 | Epitomics, Inc. | Fusion partner for production of monoclonal rabbit antibodies |
| JP5525729B2 (ja) | 2005-11-28 | 2014-06-18 | ゲンマブ エー／エス | 組換え一価抗体およびその作製方法 |
| US8080248B2 (en) * | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
| JP5307708B2 (ja) * | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| CN101528778A (zh) * | 2006-08-18 | 2009-09-09 | 埃博灵克斯股份有限公司 | 用于治疗与il-6-介导的信号传导相关的疾病和病症的针对il-6r的氨基酸序列以及包括其的多肽 |
| US8062864B2 (en) * | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| EP2259795B1 (en) * | 2008-03-26 | 2016-04-06 | Epitomics, Inc. | Anti-vegf antibody |
| EP2297202B1 (en) * | 2008-05-13 | 2016-01-13 | NovImmune SA | Anti-il-6/il-6r antibodies and methods of use thereof |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| CA2749200A1 (en) | 2009-01-29 | 2010-08-05 | Michael Bowen | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
| JP5752038B2 (ja) * | 2009-07-31 | 2015-07-22 | 愼 前田 | 癌の転移抑制剤 |
| AU2011332810A1 (en) | 2010-11-23 | 2013-06-13 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of oral mucositis |
| US8753634B2 (en) | 2011-03-03 | 2014-06-17 | Apexigen, Inc. | Anti-IL-6 receptor antibodies and methods of use |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2012
- 2012-02-28 US US13/407,293 patent/US8753634B2/en active Active
- 2012-02-28 JP JP2013556805A patent/JP6097702B2/ja not_active Expired - Fee Related
- 2012-02-28 AU AU2012223449A patent/AU2012223449A1/en not_active Abandoned
- 2012-02-28 RU RU2013144392/10A patent/RU2013144392A/ru not_active Application Discontinuation
- 2012-02-28 EP EP12752484.1A patent/EP2681243B1/en not_active Not-in-force
- 2012-02-28 BR BR112013021863A patent/BR112013021863A2/pt not_active IP Right Cessation
- 2012-02-28 CA CA2827581A patent/CA2827581A1/en not_active Abandoned
- 2012-02-28 MX MX2013009679A patent/MX342810B/es active IP Right Grant
- 2012-02-28 CN CN201280021430.0A patent/CN103502274B/zh not_active Expired - Fee Related
- 2012-02-28 WO PCT/US2012/026954 patent/WO2012118813A2/en not_active Ceased
- 2012-02-28 KR KR1020137026011A patent/KR20140043724A/ko not_active Withdrawn
-
2013
- 2013-08-27 ZA ZA2013/06451A patent/ZA201306451B/en unknown
- 2013-09-03 IL IL228275A patent/IL228275A/en active IP Right Grant
-
2014
- 2014-05-02 US US14/268,932 patent/US9951136B2/en active Active
-
2017
- 2017-04-16 IL IL251744A patent/IL251744A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014509510A5 (enExample) | ||
| RU2013144392A (ru) | Антитела к рецептору il-6 и способы применения | |
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| RU2013115927A (ru) | АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ | |
| RU2018102606A (ru) | Молекулы, связывающиеся с psl pseudomonas, и пути их применения | |
| JP2014519334A5 (enExample) | ||
| RU2018108048A (ru) | Новые анти-pd-1 антитела | |
| FI2897981T3 (fi) | Anti-CD3-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat CD3:a ja CD20:ta, ja niiden käyttöjä | |
| RU2015121755A (ru) | Антагонисты ил-6 и их применение | |
| RU2012107286A (ru) | Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2 | |
| JP2017052784A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2013538057A5 (enExample) | ||
| JP2014511179A5 (enExample) | ||
| JP2014526898A5 (enExample) | ||
| JP2011509245A5 (enExample) | ||
| FI3332006T3 (fi) | Uusia anti-PD-L1-vasta-aineita | |
| JP2018510617A5 (enExample) | ||
| JP2014503189A5 (enExample) | ||
| NZ610734A (en) | Human antibodies to the glucagon receptor | |
| CN104903352A (zh) | 多价结合蛋白组合物 | |
| JP2010526028A5 (enExample) | ||
| JP2015533795A5 (enExample) | ||
| TR201817932T4 (en) | ANTIBODIES THAT BIND STAPHYLOCOCCUS AUREUS ALPHA TOXIN SPECIFICALLY AND METHODS OF USE |